FR06C0024I2 - Anticorps humanises diriges contre la molecule d'adhesion leucocytaire vla-4 - Google Patents

Anticorps humanises diriges contre la molecule d'adhesion leucocytaire vla-4

Info

Publication number
FR06C0024I2
FR06C0024I2 FR06C0024C FR06C0024C FR06C0024I2 FR 06C0024 I2 FR06C0024 I2 FR 06C0024I2 FR 06C0024 C FR06C0024 C FR 06C0024C FR 06C0024 C FR06C0024 C FR 06C0024C FR 06C0024 I2 FR06C0024 I2 FR 06C0024I2
Authority
FR
France
Prior art keywords
directed against
humanized antibodies
antibodies directed
adhesion molecule
leukocyte adhesion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR06C0024C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Athena Neurosciences Inc
Original Assignee
Athena Neurosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Athena Neurosciences Inc filed Critical Athena Neurosciences Inc
Publication of FR06C0024I1 publication Critical patent/FR06C0024I1/fr
Application granted granted Critical
Publication of FR06C0024I2 publication Critical patent/FR06C0024I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR06C0024C 1994-01-25 2006-07-27 Anticorps humanises diriges contre la molecule d'adhesion leucocytaire vla-4 Active FR06C0024I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18626994A 1994-01-25 1994-01-25
PCT/US1995/001219 WO1995019790A1 (en) 1994-01-25 1995-01-25 Humanized antibodies against leukocyte adhesion molecule vla-4

Publications (2)

Publication Number Publication Date
FR06C0024I1 FR06C0024I1 (cs) 2006-10-13
FR06C0024I2 true FR06C0024I2 (fr) 2009-01-02

Family

ID=22684288

Family Applications (1)

Application Number Title Priority Date Filing Date
FR06C0024C Active FR06C0024I2 (fr) 1994-01-25 2006-07-27 Anticorps humanises diriges contre la molecule d'adhesion leucocytaire vla-4

Country Status (21)

Country Link
EP (2) EP1759709B1 (cs)
JP (5) JP4115517B2 (cs)
KR (1) KR100367948B1 (cs)
CN (1) CN1211123C (cs)
AT (1) ATE333895T1 (cs)
AU (1) AU703152B2 (cs)
CA (1) CA2182013C (cs)
DE (2) DE122006000043I1 (cs)
DK (2) DK1759709T3 (cs)
ES (2) ES2424292T3 (cs)
FI (1) FI117509B (cs)
FR (1) FR06C0024I2 (cs)
HU (1) HU220799B1 (cs)
LU (1) LU91271I2 (cs)
MX (1) MX9602971A (cs)
NL (1) NL300238I2 (cs)
NO (3) NO319867B1 (cs)
NZ (1) NZ279730A (cs)
PL (1) PL181827B1 (cs)
PT (1) PT804237E (cs)
WO (1) WO1995019790A1 (cs)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307025B1 (en) 1989-04-28 2001-10-23 Biogen, Inc. VCAM fusion proteins and DNA coding therefor
US5871734A (en) * 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5932214A (en) 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
NZ261259A (en) 1993-01-12 1996-12-20 Biogen Inc Humanised recombinant anti-vla4 antibody and diagnostic compositions and medicaments
CA2155303C (en) * 1993-02-09 2010-04-20 Linda C. Burkly Treatment for insulin dependent diabetes
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US7435802B2 (en) 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US7750137B2 (en) 1995-09-01 2010-07-06 Millennium Pharmaceuticals, Inc. Mucosal vascular addressins
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
AU7348798A (en) * 1997-05-09 1998-12-08 John P. Robarts Research Institute, The Method for dislodging infiltrated leukocytes from a tissue
DE19741235A1 (de) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) * 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
US7618630B2 (en) 1998-09-14 2009-11-17 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
CN1236815C (zh) * 1998-09-14 2006-01-18 德克萨斯州立大学董事会 整联蛋白拮抗剂在制备治疗多发性骨髓瘤和骨髓瘤诱发的骨吸收的药物中的应用
CN1332714C (zh) * 1999-04-22 2007-08-22 比奥根艾迪克Ma公司 整联蛋白α4亚单位的拮抗剂在制备治疗纤维变性的药物组合物中的用途
DE19922462A1 (de) 1999-05-17 2000-11-23 Aventis Pharma Gmbh Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
WO2000072881A1 (en) 1999-06-01 2000-12-07 Biogen, Inc. A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
DE60043308D1 (de) * 1999-12-16 2009-12-24 Biogen Idec Inc Verfahren zur behandlung der schädigung des zentralnervensystems durch ischämie oder durch hämorrhagie mit antagonisten von alpha4 integrin
DE10111877A1 (de) 2001-03-10 2002-09-12 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
AU2002258778C1 (en) 2001-04-13 2008-12-04 Biogen Ma Inc. Antibodies to VLA-1
DE10137595A1 (de) 2001-08-01 2003-02-13 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
DK2336184T3 (en) 2002-02-25 2015-02-16 Biogen Idec Inc Administration of agents for the treatment of inflammation.
JP2005535572A (ja) * 2002-04-12 2005-11-24 メディミューン，インコーポレーテッド 組換え抗インターロイキン−９抗体
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
TWI323265B (en) * 2002-08-06 2010-04-11 Glaxo Group Ltd Antibodies
MXPA05006384A (es) * 2002-12-17 2005-08-29 Merck Patent Gmbh Anticuerpo humanizado (h14.18) del anticuerpo 14.18 de raton enlazado a gd2 y su fusion con il-2.
CU23403A1 (es) * 2003-04-23 2009-08-04 Centro Inmunologia Molecular Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
ES2548853T3 (es) 2003-12-22 2015-10-21 Ajinomoto Co., Inc. Derivado de fenilalanina
US20090202527A1 (en) * 2004-11-19 2009-08-13 Biogen Idec Ma Inc. Treatment for multiple sclerosis
CA2629147A1 (en) * 2005-11-17 2007-05-31 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with .alpha.4.beta.7 integrin
ES2685802T3 (es) 2006-05-25 2018-10-11 Biogen Ma Inc. Antagonista de VLA-1 para su utilización en el tratamiento de un accidente cerebrovascular
CA2714335A1 (en) 2007-02-20 2008-08-28 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
TWI614028B (zh) * 2007-06-14 2018-02-11 百健Ｍａ公司 抗體調配物
MX2010004056A (es) 2007-12-13 2010-05-03 Tokuyama Corp Composicion fotocromica curable.
AU2009234253C1 (en) 2008-04-11 2015-05-07 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
NZ595464A (en) 2009-03-20 2013-08-30 Amgen Inc Alpha-4-beta-7 heterodimer specific antagonist antibody
US20120258093A1 (en) 2009-08-20 2012-10-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
HRP20171045T1 (hr) 2010-04-16 2017-10-06 Biogen Ma Inc. Protutijela anti-vla-4
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
EP4438625A3 (en) 2011-05-02 2024-12-11 Millennium Pharmaceuticals, Inc. Formulation for anti-alpha4beta7 antibody
JP6345123B2 (ja) 2012-02-16 2018-06-20 サンタラス， インコーポレイテッド 抗ｖｌａ１（ｃｄ４９ａ）抗体医薬組成物
WO2018002036A1 (en) 2016-06-28 2018-01-04 Zaklady Farmaceutyczne Polpharma Sa Recombinant production of monoclonal antibodies
US20190374639A1 (en) 2016-11-21 2019-12-12 Polpharma Biologics S.A. Aqueous pharmaceutical formulations
CN110997714B (zh) * 2017-02-17 2024-05-03 赛诺菲 对肌营养不良蛋白聚糖和层粘连蛋白-2具有特异性的多特异性结合分子
EP3635093A1 (en) 2017-06-08 2020-04-15 Polpharma Biologics S.A. Improved methods of cell culture
US12037398B2 (en) 2018-06-04 2024-07-16 Biogen Ma Inc. Anti-VLA-4 antibodies having reduced effector function
US20240301512A1 (en) 2021-01-29 2024-09-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
IL113261A (en) * 1989-09-01 1996-10-16 Hutchinson Fred Cancer Res Inhibition by peptides of lymphocyte adherence to vascular endothelium utilizing an extracellular matrix receptor-ligand interaction and pharmaceutical compositions containing said peptides
JPH07506566A (ja) * 1992-02-12 1995-07-20 バイオゲン　インコーポレイテッド 炎症性胃腸病の処置
NZ261259A (en) * 1993-01-12 1996-12-20 Biogen Inc Humanised recombinant anti-vla4 antibody and diagnostic compositions and medicaments
AUPP647298A0 (en) 1998-10-13 1998-11-05 Keystone Retaining Wall Systems, Inc. Retaining wall block

Also Published As

Publication number Publication date
EP0804237A4 (en) 2003-04-16
CA2182013A1 (en) 1995-07-27
NO2006008I1 (no) 2006-08-07
DE69535133T2 (de) 2008-08-21
EP0804237B1 (en) 2006-07-26
JP2013173738A (ja) 2013-09-05
ES2424292T3 (es) 2013-09-30
JP2006045237A (ja) 2006-02-16
EP1759709B1 (en) 2013-02-27
CN1140413A (zh) 1997-01-15
FI962958A0 (fi) 1996-07-24
PT804237E (pt) 2006-10-31
JP2009235078A (ja) 2009-10-15
AU703152B2 (en) 1999-03-18
DE69535133D1 (de) 2006-09-07
NO319867B1 (no) 2005-09-26
ATE333895T1 (de) 2006-08-15
KR970700513A (ko) 1997-02-12
NO963097L (no) 1996-09-24
KR100367948B1 (ko) 2003-07-12
NZ279730A (en) 1998-04-27
JP2013165718A (ja) 2013-08-29
ES2270425T3 (es) 2007-04-01
LU91271I2 (fr) 2006-10-02
EP1759709A1 (en) 2007-03-07
NL300238I2 (nl) 2007-05-01
NO963097D0 (no) 1996-07-24
NO2017040I2 (no) 2018-08-28
AU1696095A (en) 1995-08-08
PL315634A1 (en) 1996-11-25
NL300238I1 (cs) 2006-10-02
JP4115517B2 (ja) 2008-07-09
WO1995019790A1 (en) 1995-07-27
CN1211123C (zh) 2005-07-20
HU9602019D0 (en) 1996-09-30
MX9602971A (es) 1998-01-31
NO2017040I1 (no) 2017-08-01
JP5487382B2 (ja) 2014-05-07
HUT75129A (en) 1997-04-28
HU220799B1 (hu) 2002-05-28
EP0804237B8 (en) 2006-11-08
DK0804237T3 (da) 2006-10-16
PL181827B1 (pl) 2001-09-28
DE122006000043I1 (de) 2007-02-15
CA2182013C (en) 2007-07-17
JPH09508272A (ja) 1997-08-26
FI117509B (fi) 2006-11-15
NO2006008I2 (no) 2009-06-15
FR06C0024I1 (cs) 2006-10-13
FI962958L (fi) 1996-09-24
EP0804237A1 (en) 1997-11-05
DK1759709T3 (da) 2013-06-10

Similar Documents

Publication Publication Date Title
FR06C0024I2 (fr) Anticorps humanises diriges contre la molecule d'adhesion leucocytaire vla-4
FR2735198B1 (fr) Piece d'accastillage de type manille-cosse
DK0739275T3 (da) Fastgørelsesorgan
EP0789579A4 (en) AZA CYCLOHEXAPEPTIDE COMPOUNDS
EP0999205A4 (en) AMINOCYCLOALKAN CONNECTIONS
IT1277973B1 (it) Procedimento per l'assemblaggio di semilavorati per calze-mutanda
ITMI942358A0 (it) Peptidi ad attivita' antiinfiammatoria
NO970463D0 (no) Påföringsbånd for rörledning, uten "primer"
DE69828937D1 (de) Piece d' interposition
IT1313563B1 (it) Testina per l'applicazione di collante in zone prestabilite diprodotti in genere.
ITBO940208A0 (it) Pistola perfezionata per l'applicazione di collante
ITRM950066A0 (it) Procedimento per la produzione di poliammide con aumentata rigidita'.
FR2724251B3 (fr) Structure d'etiquetage
KR940027138U (ko) "t"형 관이음구
IT1290654B1 (it) Stazione per l'applicazione di collante su articoli.
ITMI942219A0 (it) "composti ad attivita' cardiovascolare"
IT242597Y1 (it) L'assorbiumidodeodorante
ITPS940012A0 (it) Giunto di unione, particolarmente indicato per assemblare complementi d'arredo
ITMI940717A0 (it) Composizioni farmaceutiche ad attivita' antitossica
UA1291S (uk) Штурмовий ніж-пістолет "касатка"
SE9403120L (sv) Overall "Easy"
UA27881C2 (uk) Мийно-дезінфекційний засіб "збруч-2"
ITCT940031A0 (it) "sbufi"
BR7401400U (pt) "Cool-fast
UA680S (uk) Судно-службово-роз'їздне